225 related articles for article (PubMed ID: 30312362)
61. Ertapenem for the treatment of bloodstream infections due to ESBL-producing Enterobacteriaceae: a multinational pre-registered cohort study.
Gutiérrez-Gutiérrez B; Bonomo RA; Carmeli Y; Paterson DL; Almirante B; Martínez-Martínez L; Oliver A; Calbo E; Peña C; Akova M; Pitout J; Origüen J; Pintado V; García-Vázquez E; Gasch O; Hamprecht A; Prim N; Tumbarello M; Bou G; Viale P; Tacconelli E; Almela M; Pérez F; Giamarellou H; Cisneros JM; Schwaber MJ; Venditti M; Lowman W; Bermejo J; Hsueh PR; Mora-Rillo M; Gracia-Ahulfinger I; Pascual A; Rodríguez-Baño J;
J Antimicrob Chemother; 2016 Jun; 71(6):1672-80. PubMed ID: 26907184
[TBL] [Abstract][Full Text] [Related]
62. Lack of improvement in antimicrobial prescribing after a diagnosis of Clostridium difficile and impact on recurrence.
Watson RL; Graber CJ
Am J Infect Control; 2018 Dec; 46(12):1370-1374. PubMed ID: 29779687
[TBL] [Abstract][Full Text] [Related]
63. Bloodstream infection with extended-spectrum beta-lactamase-producing Enterobacteriaceae at a tertiary care hospital in New Zealand: risk factors and outcomes.
Freeman JT; McBride SJ; Nisbet MS; Gamble GD; Williamson DA; Taylor SL; Holland DJ
Int J Infect Dis; 2012 May; 16(5):e371-4. PubMed ID: 22401750
[TBL] [Abstract][Full Text] [Related]
64. Beta-lactam/beta-lactamase inhibitors versus carbapenem for bloodstream infections due to extended-spectrum beta-lactamase-producing Enterobacteriaceae: systematic review and meta-analysis.
Sfeir MM; Askin G; Christos P
Int J Antimicrob Agents; 2018 Nov; 52(5):554-570. PubMed ID: 30081138
[TBL] [Abstract][Full Text] [Related]
65. The effect of probiotics on the incidence of Clostridioides difficile: Retrospective cohort analysis.
Saltzman T; Fazzari M; Chung S; Cunha BA; Blum S
Am J Infect Control; 2020 Feb; 48(2):184-188. PubMed ID: 31606256
[TBL] [Abstract][Full Text] [Related]
66. Risk of Clostridium difficile infection in hospitalized patients receiving metronidazole for a non-C difficile infection.
Rodriguez S; Hernandez MB; Tarchini G; Zaleski M; Vatanchi M; Cardona L; Castro-Pavia F; Schneider A
Clin Gastroenterol Hepatol; 2014 Nov; 12(11):1856-61. PubMed ID: 24681079
[TBL] [Abstract][Full Text] [Related]
67. Epidemiological, clinical, and microbiological characteristics of carbapenemase-producing Enterobacteriaceae bloodstream infection in the Republic of Korea.
Park JW; Lee H; Park SY; Kim TH
Antimicrob Resist Infect Control; 2019; 8():48. PubMed ID: 30873279
[TBL] [Abstract][Full Text] [Related]
68. Prediction of Fluoroquinolone Resistance in Gram-Negative Bacteria Causing Bloodstream Infections.
Dan S; Shah A; Justo JA; Bookstaver PB; Kohn J; Albrecht H; Al-Hasan MN
Antimicrob Agents Chemother; 2016 Apr; 60(4):2265-72. PubMed ID: 26833166
[TBL] [Abstract][Full Text] [Related]
69. Asymptomatic rectal colonization with carbapenem-resistant Enterobacteriaceae and Clostridium difficile among residents of a long-term care facility in New York City.
Prasad N; Labaze G; Kopacz J; Chwa S; Platis D; Pan CX; Russo D; LaBombardi VJ; Osorio G; Pollack S; Kreiswirth BN; Chen L; Urban C; Segal-Maurer S
Am J Infect Control; 2016 May; 44(5):525-32. PubMed ID: 26796684
[TBL] [Abstract][Full Text] [Related]
70. Epidemiology and Burden of Bloodstream Infections Caused by Extended-Spectrum Beta-Lactamase Producing Enterobacteriaceae in a Pediatric Hospital in Senegal.
Ndir A; Diop A; Faye PM; Cissé MF; Ndoye B; Astagneau P
PLoS One; 2016; 11(2):e0143729. PubMed ID: 26867226
[TBL] [Abstract][Full Text] [Related]
71. Development of a risk prediction model for hospital-onset Clostridium difficile infection in patients receiving systemic antibiotics.
Tilton CS; Johnson SW
Am J Infect Control; 2019 Mar; 47(3):280-284. PubMed ID: 30318399
[TBL] [Abstract][Full Text] [Related]
72. Impact of fluoroquinolone resistance in Gram-negative bloodstream infections on healthcare utilization.
Brigmon MM; Bookstaver PB; Kohn J; Albrecht H; Al-Hasan MN
Clin Microbiol Infect; 2015 Sep; 21(9):843-9. PubMed ID: 26003282
[TBL] [Abstract][Full Text] [Related]
73. Characterization and Clinical Impact of Bloodstream Infection Caused by Carbapenemase-Producing Enterobacteriaceae in Seven Latin American Countries.
Villegas MV; Pallares CJ; Escandón-Vargas K; Hernández-Gómez C; Correa A; Álvarez C; Rosso F; Matta L; Luna C; Zurita J; Mejía-Villatoro C; Rodríguez-Noriega E; Seas C; Cortesía M; Guzmán-Suárez A; Guzmán-Blanco M
PLoS One; 2016; 11(4):e0154092. PubMed ID: 27104910
[TBL] [Abstract][Full Text] [Related]
74. Receipt of Antibiotics in Hospitalized Patients and Risk for Clostridium difficile Infection in Subsequent Patients Who Occupy the Same Bed.
Freedberg DE; Salmasian H; Cohen B; Abrams JA; Larson EL
JAMA Intern Med; 2016 Dec; 176(12):1801-1808. PubMed ID: 27723860
[TBL] [Abstract][Full Text] [Related]
75. Current management of Clostridioides (Clostridium) difficile infection in adults: a summary of recommendations from the 2017 IDSA/SHEA clinical practice guideline.
Ma J; Dubberke E
Pol Arch Intern Med; 2019 Mar; 129(3):189-198. PubMed ID: 30457126
[TBL] [Abstract][Full Text] [Related]
76. Factors influencing antimicrobial resistance and outcome of Gram-negative bloodstream infections in children.
Ivády B; Kenesei É; Tóth-Heyn P; Kertész G; Tárkányi K; Kassa C; Ujhelyi E; Mikos B; Sápi E; Varga-Heier K; Guóth G; Szabó D
Infection; 2016 Jun; 44(3):309-21. PubMed ID: 26546372
[TBL] [Abstract][Full Text] [Related]
77. The tipping point: patients predisposed to Clostridium difficile infection and a hospital antimicrobial stewardship programme.
Stites SD; Cooblall CA; Aronovitz J; Singletary SB; Micklow K; Sjeime M
J Hosp Infect; 2016 Nov; 94(3):242-248. PubMed ID: 27742079
[TBL] [Abstract][Full Text] [Related]
78. Risk factors for Clostridium difficile infection in hospitalized patients with community-acquired pneumonia.
Chalmers JD; Akram AR; Singanayagam A; Wilcox MH; Hill AT
J Infect; 2016 Jul; 73(1):45-53. PubMed ID: 27105657
[TBL] [Abstract][Full Text] [Related]
79. Time to positivity of blood cultures supports antibiotic de-escalation at 48 hours.
Pardo J; Klinker KP; Borgert SJ; Trikha G; Rand KH; Ramphal R
Ann Pharmacother; 2014 Jan; 48(1):33-40. PubMed ID: 24259644
[TBL] [Abstract][Full Text] [Related]
80. Breakthrough bloodstream infections in critically ill non-neutropenic patients: higher incidence and better survival than non-breakthrough infections.
Papadimitriou-Olivgeris M; Kolonitsiou F; Solomou A; Karamouzos V; Anastassiou ED; Christofidou M; Spiliopoulou I; Fligou F; Marangos M
J Med Microbiol; 2019 Oct; 68(10):1544-1551. PubMed ID: 31436523
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
